FIBRALIGN CORPORATION
Fibralign Corporation utilizes Nanoweave® a proprietary scaffolding technology to develop advanced biomedical devices. Fibralign has launched its first product, the BioBridge® Collagen Matrix, and is now engaging in clinical studies to evaluate its use for treating and preventing secondary lymphedema, as well as advancing R&D development for new applications for treating ischemia and novel delivery devices for use with stem cells and gene therapy.
FIBRALIGN CORPORATION
Industry:
Biotechnology Clinical Trials Medical Medical Device Therapeutics
Founded:
2007-01-01
Address:
Sunnyvale, California, United States
Country:
United States
Website Url:
http://www.fibralignbio.com
Total Employee:
1+
Status:
Active
Contact:
8313358348
Email Addresses:
[email protected]
Total Funding:
179.96 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Google Tag Manager WordPress Google Universal Analytics Global Site Tag Mobile Non Scaleable Content Sitelinks Search Box
Current Advisors List
Current Employees Featured
Founder
Investors List
AngelMD
AngelMD investment in Venture Round - Fibralign Corporation
MedTech Innovator
MedTech Innovator investment in Grant - Fibralign Corporation
National Science Foundation
National Science Foundation investment in Grant - Fibralign Corporation
Official Site Inspections
http://www.fibralignbio.com Semrush global rank: 5.97 M Semrush visits lastest month: 1.38 K
- Host name: 44.173.155.104.bc.googleusercontent.com
- IP address: 104.155.173.44
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Fibralign Corporation"
Home - Fibralign
Apr 15, 2021 NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment SAN FRANCISCO, June 10, 2021 /PRNewswire/ -- The UCSF Rosenman Institute …See details»
About Us - Fibralign
Fibralign Corp 32930 Alvarado-Niles Rd. Suite 350 Union City CA 94587See details»
About Us - Fibralign
Https://pubmed.ncbi.nlm.nih.gov/34549427/ Dionyssiou, Dimitrios & Demiri, Efterpi. (2021). A comprehensive treatment algorithm for patients requiring simultaneous breast and …See details»
Fibralign Corporation Management Team | Org Chart
Fibralignbio.com; Paul-André Arcache Product Specialist at Fibralign Corporation Paris, FR View. View Similar People. Related Companies RIOTORO. 3 $6m Alan CompuTech International. 6 …See details»
Fibralign Corporation - Crunchbase Company Profile
Fibralign Corporation utilizes Nanoweave® a proprietary scaffolding technology to develop advanced biomedical devices. Fibralign has launched its first product, the BioBridge® Collagen Matrix, and is now engaging in clinical studies to …See details»
Fibralign Company Profile 2024: Valuation, Funding & Investors
Nov 27, 2017 Fibralign General Information Description. Developer of advanced therapeutic biomedical devices designed to target unmet needs in regenerative medicine. The company's …See details»
Fibralign Corporation - Company Profile & Staff Directory
Fibralign Corporation is a Stanford University spin-out that produces advanced therapeutic biomedical devices, utilizing its powerful patented Nanoweave® technology for creating 3D …See details»
Investor Relations - Fibralign
The World Health Organization (WHO) estimates that 15 million patients worldwide suffer from cancer-related lymphedema. It is reported that there are over 150,000 new cases each year in …See details»
Fibralign Corporation Company Profile - MedTech Innovator
Fibralign’s first product BioBridge is developed to address Secondary Lymphedema, a global chronic debilitating disease that affects over 120M people and has no cure (World Health Org, …See details»
Fibralign Corporation - LinkedIn
Fibralign Corporation is a Stanford University spin-out that produces advanced therapeutic biomedical devices, utilizing its powerful patented Nanoweave® technology for creating 3D …See details»
Fibralign - UCSF Rosenman Institute
Dec 15, 2023 Fibralign Corporation produces therapeutic devices using its patented Nanoweave technology that creates bio-scaffolding which precisely mimics human tissue.See details»
BioBridge - Fibralign
The BioBridge ® Collagen Matrix is a CE mark Class III device approved for use in the surgical treatment of lymphedema.. This novel thread-like surgical mesh is made of medical-grade …See details»
Contact - Fibralign
[email protected] +1 415 902 4721. Fibralign Corp. JLabs @ SSF 3rd Floor 329 Oyster Point Blvd South San Francisco, CA 94080 [email protected] +1 415 902 4721. Fibralign …See details»
Clinical Studies - Fibralign
Fibralign is currently conducting three clinical studies to further demonstrate clinical benefit for addressing lymphedema: LYMPHBRIDGE is a multi-site blinded clinical study evaluating the …See details»
Fibralign Announces CE Mark Approval for BioBridge® - BioSpace
Sep 14, 2020 Fibralign also received an updated ISO 13485:2016 certification of its quality management system. This certification demonstrates the company's focus on quality and its …See details»
Fibralign Announces CE Mark Approval for BioBridge®
Sep 14, 2020 Fibralign also received an updated ISO 13485:2016 certification of its quality management system. This certification demonstrates the company’s focus on quality and its …See details»
Fibralign Announces Start of European Lymphedema Prevention …
Feb 9, 2021 In Europe: Albert Huttenga, [email protected] +31 651 750 078 Greg King, CEO/President Fibralign Corp. [email protected] , +1 415 902 4721 Fibralign …See details»
BioBridge - Fibralign
The BioBridge Collagen Matrix is intended to reinforce soft tissue where weakness and deficiencies exist, specifically, for reinforcement of soft tissue repaired by sutures or suture …See details»
Fibralign Announces Start of European Lymphedema Prevention …
Feb 9, 2021 In Europe: Albert Huttenga, [email protected] +31 651 750 078 Greg King, CEO/President Fibralign Corp. [email protected], +1 415 902 4721 Site Navigation …See details»
Fibralign Announces Strategic Partnership with Terumo
Jun 3, 2020 https://www.fibralignbio.com. About Terumo. Terumo (TSE:4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” …See details»